US 12,186,313 B2
Pyridazinone compounds and their use as DAAO inhibitors
William Farnaby, Cambridge (GB); Charlotte Fieldhouse, Cambridge (GB); Katherine Hazel, Cambridge (GB); Catrina Kerr, Dundee (GB); Natasha Kinsella, Kampala (UG); David Livermore, Cambridge (GB); Kevin Merchant, Cambridge (GB); and David Miller, Cambridge (GB)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Filed by Takeda Pharmaceutical Company Ltd., Osaka (JP)
Filed on Aug. 30, 2021, as Appl. No. 17/461,757.
Application 17/461,757 is a division of application No. 16/580,095, filed on Sep. 24, 2019, granted, now 11,129,828.
Application 15/899,561 is a division of application No. 15/014,336, filed on Feb. 3, 2016, granted, now 9,931,340, issued on Apr. 3, 2018.
Application 15/014,336 is a division of application No. 14/240,045, granted, now 9,290,456, issued on Mar. 22, 2016, previously published as PCT/GB2012/000672, filed on Aug. 21, 2012.
Application 16/580,095 is a continuation of application No. 15/899,561, filed on Feb. 20, 2018, granted, now 10,463,663, issued on Nov. 5, 2019.
Claims priority of application No. 1114399 (GB), filed on Aug. 22, 2011; application No. 1118658 (GB), filed on Oct. 27, 2011; and application No. 1203533 (GB), filed on Feb. 29, 2012.
Prior Publication US 2022/0008416 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/50 (2006.01); A61K 31/501 (2006.01); A61K 45/06 (2006.01); C07D 237/14 (2006.01); C07D 237/16 (2006.01); C07D 237/18 (2006.01); C07D 237/22 (2006.01); C07D 401/06 (2006.01); C07D 401/10 (2006.01); C07D 405/06 (2006.01); C07D 407/10 (2006.01); C07F 7/08 (2006.01)
CPC A61K 31/50 (2013.01) [A61K 31/501 (2013.01); A61K 45/06 (2013.01); C07D 237/14 (2013.01); C07D 237/16 (2013.01); C07D 237/18 (2013.01); C07D 237/22 (2013.01); C07D 401/06 (2013.01); C07D 401/10 (2013.01); C07D 405/06 (2013.01); C07D 407/10 (2013.01); C07F 7/0812 (2013.01)] 10 Claims
 
1. A method of treating at least one symptom or condition associated with schizophrenia in a patient in need thereof, the method comprising administering a therapeutically effective amount of a compound that is 4-hydroxy-6-{2-[4-(trifluoromethyl)phenyl]ethyl}pyridazin-3(2H)-one or a pharmaceutically acceptable salt thereof to the patient, wherein the compound is in crystalline form.